Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.83 |
| ▸ | CA9 | Q16790 | 4/20 | 0.77 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.75 |
| ▸ | NT5E | P21589 | 3/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | TOP2A | P11388 | 1/20 | 0.73 |
| ▸ | RELA | Q04206 | 1/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214200 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL14345008 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL6112807 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL2733537 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| Water SCHEMBL8584387 | 0.99 | PTGES (0.82) | PTGESCA9SLC10A1NT5EPTPN1 | |
| Ether SCHEMBL8586168 | 0.96 | PTGES (0.78) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL13855630 | 0.93 | PTGES (0.72) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL5454249 | 0.93 | NT5E (0.75) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL13573803 | 0.93 | NT5E (0.75) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL5956476 | 0.92 | PTGES (0.74) | PTGESCA9SLC10A1NT5EPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110224159-A1 | BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS | Universite du Quebec a Chicoutime (CA) | 2011-09-15 | — | — | US | disclosed |
| US-20100273801-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | Valition teknillinen tutikimuskeskus (FI) | 2010-10-28 | — | — | US | disclosed |
| US-20100273801-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | Valition teknillinen tutikimuskeskus (FI) | 2010-10-28 | — | — | US | disclosed |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-05 | — | — | US | disclosed |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-05 | — | — | US | disclosed |
| US-20100190795-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-07-29 | — | — | US | disclosed |
| US-20100190795-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-07-29 | — | — | US | disclosed |
| WO-2007141389-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | PTGES 1561/4885CA9 2040/4885SLC10A1 1476/4885 |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | BET1, PGGT1B, RABGGTB | PTGES 610/4885CA9 451/4885SLC10A1 2832/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | PTGES 1561/4885CA9 2040/4885SLC10A1 1476/4885 |
| US-20100273801-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | BET1, CUTA, BECN1 | PTGES 947/4885CA9 3167/4885SLC10A1 2928/4885 |
| US-20110224159-A1 | BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS | BET1, SI, ERG28 | PTGES 1432/4885CA9 58/4885SLC10A1 2435/4885 |
| US-20100190795-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | BET1, BECN1, PGGT1B | PTGES 533/4885CA9 4612/4885SLC10A1 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.